

Revision date: 05-Jan-2007 Version: 1.1 Page 1 of 6

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Xylometazoline and Hyaluronic Acid Nasal Spray

Trade Name: OLYNTH HA
Chemical Family: Mixture

Intended Use: Pharmaceutical product used as decongestant, bronchodilator, vasoconstrictor

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Xylometazoline hydrochloride	1218-35-5	214-936-4	<1.0
Glycerin, USP	56-81-5	200-289-5	*

Ingredient	CAS Number	EU EINECS List	%
Hyaluronic Acid Sodium	9004-61-9	232-678-0	<1.0
Sodium dihydrogen phosphate dihydrate	13472-35-0	Not listed	*
Sodium chloride	7647-14-5	231-598-3	*
Sorbitol syrup	68425-17-2	270-337-8	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	*
Deionized water	7732-18-5	231-791-2	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance: Colorless liquid

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: Harmful if swallowed . Harmful if inhaled . May cause irritation (based on components) .

Long Term: May cause effects on cardiovascular system, central nervous system, respiratory system.

Known Clinical Effects: Clinical use may cause effect on the cardiovascular system, central nervous system,

respiratory system local irritation.

EU Indication of danger: Not classified

Material Name: Xylometazoline and Hyaluronic Acid Nasal Page 2 of 6

Spray

Revision date: 05-Jan-2007 Version: 1.1

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Use appropriate ventilation. Avoid contact with eyes, skin and clothing. Avoid breathing vapor

or mist.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Glycerin, USP

Material Name: Xylometazoline and Hyaluronic Acid Nasal Page 3 of 6

Spray

Revision date: 05-Jan-2007 Version: 1.1

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

= 5 mg/m³ TWA = 10 mg/m³ TWA

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA Australia TWA = 10 mg/m³ TWA

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: Not required for the normal use of this product. Whenever excessive air contamination (dust,

mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be

used to minimize exposure.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:LiquidColor:ColorlessMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD 50 4000 mg/kg

Xylometazoline hydrochloride

Rat Oral LD50 122 mg/kg

Rat Inhalation LC50/4h >0.47 <1.08 mg/L

Glycerin, USP

Mouse Oral LD50 4090 mg/kg
Rat Oral LD50 12.6 g/kg
Rabbit Dermal LD50 > 10 g/kg

Rat Inhalation LC50 1hr > 570 mg/m³

Material Name: Xylometazoline and Hyaluronic Acid Nasal Page 4 of 6

Spray

Revision date: 05-Jan-2007 Version: 1.1

Rat Dermal LD 50 >21.9 g/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

<u>Irritation / Sensitization: (Study Type, Species, Severity)</u>

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Sodium phosphate, dibasic

Eye Irritation Rabbit Mild Skin Irritation Rabbit Mild

Xylometazoline hydrochloride

Skin Irritation Rabbit Non-irritating

Glycerin, USP

Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium chloride

10 Day(s) Rat Oral 12500 mg/kg LOAEL Kidney, Ureter, Bladder

Xylometazoline hydrochloride

3 Month(s) Rat Oral 6 mg/kg/day NOAEL Cardiovascular system 3 Month(s) Dog Oral 1 mg/kg/day LOAEL Cardiovascular system

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Xylometazoline hydrochloride

Bacterial Mutagenicity (Ames) Bacteria Negative

Micronucleus Mouse Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Releases to the environment should be avoided. The environmental characteristics of this

material have not been fully evaluated.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP

Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L Daphnia Magna (Water Flea) EC50 24 Hours >500 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum

dose tested.

Material Name: Xylometazoline and Hyaluronic Acid Nasal Page 5 of 6

Spray

Revision date: 05-Jan-2007 Version: 1.1

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Xylometazoline hydrochloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present
EU EINECS List

214-936-4

Hyaluronic Acid Sodium

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling

XU

Present

Schedule 4

for Drugs and Poisons:

EU EINECS List 232-678-0

Sodium dihydrogen phosphate dihydrate

Australia (AICS): Present

Sodium chloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
231-598-3

Sorbitol syrup

Inventory - United States TSCA - Sect. 8(b) Present

Material Name: Xylometazoline and Hyaluronic Acid Nasal Page 6 of 6

Spray

Revision date: 05-Jan-2007 Version: 1.1

Australia (AICS): Present EU EINECS List 270-337-8

Sodium phosphate, dibasic

CERCLA/SARA Hazardous Substances = 2270 kg final RQ and their Reportable Quantities: = 5000 lb final RQ

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
231-448-7

Glycerin, USP

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

200-289-5

Deionized water

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Fresent

EU EINECS List

231-791-2

16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 5 - Fire

Fighting Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated

Section 12 - Ecological Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet